MORF Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 108019 min ago

@ $37.26

Išleistas: 14 vas. 2024 @ 22:46

Grąža: -24.93%

Ankstesnis signalas: vas. 14 - 21:06

Ankstesnis signalas: Pirkimas

Grąža: 0.38 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	341 998
Vidutinė apimtis	498 550
Rinkos kapitalizacija	1.40B
EPS	$0 ( 2024-04-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.77
ATR14	$0.0490 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.64
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

Tūris Koreliacija

Ilgas: -0.12 (neutral)

Trumpas: 0.87 (strong)

Signal:(54.103) Same movement expected

Morphic Holding Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Morphic Holding Inc Koreliacija - Valiuta/Žaliavos

0.51
( weak )

0.55
( weak )

0.00
( neutral )

0.10
( neutral )

-0.05
( neutral )

-0.70
( moderate negative )

Morphic Holding Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$521 000
Bruto pelnas:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2023
Pajamos:	$521 000
Bruto pelnas:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2022
Pajamos:	$70.81M
Bruto pelnas:	$69.80M (98.58 %)
EPS:	$-1.550

FY	2021
Pajamos:	$19.79M
Bruto pelnas:	$19.79M (100.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.